Meconiuom from newborns is typically used to screen for drug use by the mother during pregnancy. Drugs accumulate in meconium by fetal excretion into bile and amniotic fluid. Meconium is typically screened for various drug categories via immunoassay.
The goal of obtaining no false negative results was achieved with this new LDTD-MS/MS method. By combining the efficient and complete hydrolysis capability of IMCSzyme® with the ultrafast quantification ability of the LDTD-MS/MS system, meconium patient samples were able to be prepared and screened for 26 different drug analytes in a matter of minutes.
Summary by IMCS from the technical poster “Meconium Targeted Drug Screening in 9 seconds per Sample Using Laser Diode Thermal Desorption Mass Spectrometry (LDTD-MS/MS)” presented by Serge Auger - Phytronix at ASMS 2016